

according to Regulation (EC) No. 1907/2006

Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 1567794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017				
SECTION	1: Identification of	the substance/mixt	ture and of the company/undertaking				
1.1 Produc	ct identifier						
Trade	name	: Ezetimibe Granules Formulation					
Use of	n t identified uses of t f the Sub- e/Mixture	he substance or mixit : Pharmaceutical	ture and uses advised against				
1.3 Details of the supplier of the safety data sheet							
Comp	any	: Organon & Co. Shotton Lane NE23 3JU Cram	ilington NU - Great Britain				

: 44 1 670 59 30 00

: EHSSTEWARD@organon.com

E-mail address of person responsible for the SDS

1.4 Emergency telephone number

215-631-6999

Telephone

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Long-term (chronic) aquatic hazard, Category 2 H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	× 1
Hazard statements	:	H411 Toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention: P273 Avoid release to the environment.
		Response: P391 Collect spillage.



according to Regulation (EC) No. 1907/2006

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1567794-00009	Date of first issue: 18.04.2017

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components			
Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ezetimibe	163222-33-1	Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1	>= 2.5 - < 10
Sodium n-dodecyl sulfate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412	>= 1 - < 2.5

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	In the case of accident or if you feel unwell, seek medical vice immediately. When symptoms persist or in all cases of doubt seek med advice.	
Protection of first-aiders	First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for exposure exists (see section 8).	
If inhaled	If inhaled, remove to fresh air. Get medical attention if symptoms occur.	
In case of skin contact	In case of contact, immediately flush skin with plenty of wa Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.	ater.
In case of eye contact	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.	

according to Regulation (EC) No. 1907/2006




Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021		0S Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017		
If swallowed		:	Get medical atte	NOT induce vomiting. ntion if symptoms occur. roughly with water.		
4.2 Most i	mportant symptoms a	nd e	effects, both acut	e and delayed		
Risks		:	Dust contact with	the eyes can lead to mechanical irritation.		
4.3 Indication of any immediate n Treatment				lical attention and special treatment needed Treat symptomatically and supportively.		
SECTION	1 5: Firefighting meas	sur	es			
-	uishing media ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (Dry chemical			
Unsui media	itable extinguishing a	ng : None known.				
5.2 Specia	al hazards arising from	the	e substance or m	ixture		
-	fic hazards during fire-			bustion products may be a hazard to health.		
Haza ucts	rdous combustion prod-	:	Carbon oxides Nitrogen oxides (Fluorine compou Sulphur oxides Metal oxides			
5.3 Advice	e for firefighters					
	al protective equipment efighters	:		e, wear self-contained breathing apparatus. tective equipment.		
Speci ods	fic extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. aged containers from fire area if it is safe to do		

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment.
		Follow safe handling advice (see section 7) and personal pro-
		tective equipment recommendations (see section 8).





Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 1567794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017
6.2 Enviro	onmental precautions		
Enviro	onmental precautions	Prevent furthe Retain and di	e to the environment. er leakage or spillage if safe to do so. spose of contaminated wash water. ies should be advised if significant spillages ntained.
6.3 Metho	ds and material for co	ntainment and cle	eaning up
Metho	ods for cleaning up	tainer for disp Avoid dispers with compres Dust deposits es, as these r leased into th Local or natio posal of this r employed in t mine which re Sections 13 a	al of dust in the air (i.e., clearing dust surfaces

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	•	
Technical measures	causi	electricity may accumulate and ignite suspended dust ng an explosion.
		de adequate precautions, such as electrical grounding
		onding, or inert atmospheres.
Local/Total ventilation		only with adequate ventilation.
Advice on safe handling	: Do no	ot get on skin or clothing.
	Do no	ot breathe dust.
	Do no	ot swallow.
	Avoid	contact with eyes.
		le in accordance with good industrial hygiene and safety
		ce, based on the results of the workplace exposure as-
	sessr	
		nize dust generation and accumulation.
		container closed when not in use.
		away from heat and sources of ignition.
		precautionary measures against static discharges.
		care to prevent spills, waste and minimize release to the
		onment.
Hygiene measures		osure to chemical is likely during typical use, provide eye
Trygiene measures		ng systems and safety showers close to the working
		• • • •
		. When using do not eat, drink or smoke. Wash contami-
	nated	clothing before re-use.



according to Regulation (EC) No. 1907/2006

Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021		DS Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017	
2.0	09.04.2021	10	67794-00009		
7.2 Con	ditions for safe storage,	inc	luding any incom	patibilities	
Requirements for storage areas and containers			Keep in properly labelled containers. Store in accordance with the particular national regulations.		
Adv	vice on common storage	:	Do not store with Strong oxidizing a	the following product types: agents	
•	cific end use(s) ecific use(s)	:	No data available		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis				
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m3	GB EH40				
	halable dust a sampling is un MDHS14/4 G ble, thoracic a hazardous to in air equal to mg.m-3 8-hou ject to COSHI have been as the appropriat of sizes. The entry into the depend on the fractions for li ble dust appro- and mouth du respiratory tra to the gas exc material are g	Further information: For the purposes of these limits, respirable dust and in- halable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respira- ble, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m-3 8-hour TWA of inhalable dust or 4 mg.m-3 8-hour TWA of respirable dust. This means that any dust will be sub- ject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'., Inhala- ble dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory						
		their own assigned WEL, all the relevant limits should be complied with. TWA (Respirable dust)						
	Further information: For the purposes of these limits, respirable dust and in- halable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respira- ble, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m-3 8-hour TWA of inhalable dust or 4 mg.m-3 8-hour TWA of respirable dust. This means that any dust will be sub- ject to COSHH if people are exposed to dust above these levels. Some dusts							

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

rsion S	Revision Date 09.04.2021			ate of last issue: 10.10.2020 ate of first issue: 18.04.2017	
		the appropriat of sizes. The l entry into the depend on the fractions for lin ble dust appro and mouth du respiratory tra to the gas exc material are g	te limits., Most indust behaviour, deposition human respiratory se nature and size of mit-setting purposes oximates to the fract ring breathing and it ct. Respirable dust change region of the iven in MDHS14/4.	s and exposure to these must strial dusts contain particles of on and fate of any particular particular particular particular particular particular particular particular particular. HSE distinguishes the particle. HSE distinguishes the particle. HSE distinguishes to a fairborne material that each s therefore available and 'respition approximates to the fraction to a lung. Fuller definitions and each Where dusts contain compore elevant limits should be comp	f a wide range article after e that it elicits, es two size rable'., Inhala- enters the nose sition in the hat penetrates xplanatory nents that have
			STEL (inhalable dust)	20 mg/m3	GB EH40
Ezetir		halable dust a sampling is ur MDHS14/4 Ge ble, thoracic a hazardous to in air equal to mg.m-3 8-hou ject to COSHI have been as the appropriat of sizes. The I entry into the depend on the fractions for lin ble dust appro- and mouth du respiratory tra to the gas exc material are g	the those fractions of indertaken in accord eneral methods for and inhalable aeroso health includes dus or greater than 10 in TWA of respirable of fpeople are expo- signed specific WEI the limits., Most indus behaviour, deposition human respiratory se enature and size of mit-setting purposes oximates to the fract ring breathing and i ct. Respirable dust change region of the iven in MDHS14/4.	bess of these limits, respirable f airborne dust which will be of ance with the methods descril sampling and gravimetric ana ols., The COSHH definition of t of any kind when present at mg.m-3 8-hour TWA of inhala e dust. This means that any du used to dust above these level as and exposure to these must strial dusts contain particles of on and fate of any particular particular system, and the body respons the particle. HSE distinguishes therefore available and 'respiration string. Fuller definitions and e Where dusts contain compor elevant limits should be comp 25 μg/m3 (OEB 3)	collected when bed in lysis or respira- a substance a concentration ble dust or 4 ust will be sub- s. Some dusts st comply with f a wide range article after that it elicits, es two size rable'., Inhala- enters the nose sition in the hat penetrates xplanatory nents that have
		1	Wipe limit		Internal
				250 µg/100 cm ²	internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m3
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m3
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	24 mg/kg bw/day



according to Regulation (EC) No. 1907/2006

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1567794-00009	Date of first issue: 18.04.2017

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium n-dodecyl sulfate	Fresh water	0.176 mg/l
	Marine water	0.018 mg/l
	Sewage treatment plant	1.35 mg/l
	Fresh water sediment	6.97 mg/kg dry weight (d.w.)
	Marine sediment	0.697 mg/kg dry weight (d.w.)
	Soil	1.29 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment							
Eye protection	:	Wear the following personal protective equipment: Safety goggles Equipment should conform to BS EN 166					
Hand protection							
Material	:	Chemical-resistant gloves					
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous sub- stance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.					
Skin and body protection Respiratory protection	:	Skin should be washed after contact. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143					
Filter type	:	Particulates type (P)					

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

nular
te
data available
data available

according to Regulation (EC) No. 1907/2006




Ezetimibe Granules Formulation

Vers 2.6	sion	Revision Date: 09.04.2021		S Number: 37794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017
	pН		:	No data available	9
	Melting	point/freezing point	:	No data available)
		oiling point and boiling	:	No data available)
	range Flash p	oint	:	Not applicable	
	Evapora	ation rate	:	No data available)
	Flamma	ability (solid, gas)	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans.
	Flamma	ability (liquids)	:	No data available)
		explosion limit / Upper bility limit	:	No data available	•
		explosion limit / Lower bility limit	:	No data available	
	Vapour	pressure	:	No data available	
	Relative vapour density		:	No data available)
	Density		:	No data available)
		er solubility n coefficient: n-	:	No data available No data available	
	Auto-igi	nition temperature	:	No data available)
	Decom	position temperature	:	No data available)
	Viscosit Visc	ty osity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance of	r mixture is not classified as oxidizing.
9.2		formation			
		lar weight	:	No data available	
	Particle	size	:	No data available)

SECTION 10: Stability and reactivity


10.1 Reactivity

Not classified as a reactivity hazard.





Version 2.6	Revision Date: 09.04.2021	-	0S Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017			
10.2 Che	mical stability						
Stab	ble under normal condition	NS.					
10.3 Pos	sibility of hazardous rea	actio	ons				
Hazardous reactions : May form explosive dust-air mixture during processing, han dling or other means. Can react with strong oxidizing agents.							
10.4 Conditions to avoid							
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.							
10.5 Inco	ompatible materials						
Mate	erials to avoid	:	Oxidizing agents	6			
No h	ardous decomposition p nazardous decomposition	pro	ducts are known.				
	N 11: Toxicological in						
	mation on likely routes of		Inhalation				
	osure	•	Skin contact Ingestion Eye contact				
	te toxicity classified based on availa	ıble	information.				
Pro	duct:						
Acut	te oral toxicity	:	Acute toxicity est Method: Calculat	imate: > 2,000 mg/kg ion method			
<u>Con</u>	nponents:						
Ezet	timibe:						
Acut	te oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg			
			LD50 (Mouse): >	5,000 mg/kg			
			LD50 (Dog): > 3,0	000 mg/kg			
Acut	te inhalation toxicity	:	Remarks: No data	a available			
Acut	te dermal toxicity	:	Remarks: No dat	a available			
	te toxicity (other routes of inistration)	:	LD50 (Rat): > 2,0 Application Route				
			LD50 (Mouse): > Application Route	1,000 - < 2,000 mg/kg e: Intraperitoneal			





Ezetimibe Granules Formulation

Vers 2.6	sion	Revision Date: 09.04.2021		OS Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017			
	Sodiu	m n-dodecyl sulfate:						
	Acute oral toxicity			LD50 (Rat): 1,200 Method: OECD T				
	Acute dermal toxicity		:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Remarks: Based on data from similar materials				
		orrosion/irritation	L 1-	in farma a tin a				
		assified based on availa onents:	eidi	information.				
	Ezetin							
	Specie Result	S	:	Rabbit No skin irritation				
	Sodiu	m n-dodecyl sulfate:						
	Species Result			: Rabbit : Skin irritation				
		is eye damage/eye irr assified based on availa						
	<u>Comp</u>	onents:						
	Ezetim	nibe:						
	Specie Result		:	Rabbit No eye irritation				
	Sodiu	m n-dodecyl sulfate:						
	Species Method Result		:	eline 405 s on the eye				
	Respir	ratory or skin sensitis	atic	on				
		ensitisation assified based on availa	ıble	information.				
	-	ratory sensitisation assified based on availa	ıble	information.				
		onents:						
	Ezetim	nibe:						
	Test Ty Specie Result	S	::	Maximisation Tes Guinea pig negative	t			

Sodium n-dodecyl sulfate:

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021	SDS Number: 1567794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017				
	ılt	: Skin contact : Guinea pig : negative					
Gerr	n cell mutagenicity						
Not	classified based on ava	ilable information.					
<u>Com</u>	ponents:						
Ezet	imibe:						
Gen	otoxicity in vitro		Bacterial reverse mutation assay (AMES) stivation: with and without metabolic activation tive				
			Chromosomal aberration : Human lymphocytes tive				
Gene	otoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative					
Sodi	um n-dodecyl sulfate	:					
	otoxicity in vitro	: Test Type: E	Bacterial reverse mutation assay (AMES) CD Test Guideline 471 Itive				
		Test Type: Ir Result: nega	n vitro mammalian cell gene mutation test tive				
Gene	otoxicity in vivo	Species: Mo Application F	: Test Type: Rodent dominant lethal test (germ cell) (in vivo) Species: Mouse Application Route: Ingestion Result: negative				


Carcinogenicity

Not classified based on available information.

Components:

Ezetimibe:

Species Application Route Exposure time Result	:	Rat, female oral (feed) 104 weeks negative
Species Application Route Exposure time		Rat, male oral (feed) 104 weeks





Versio 2.6	on	Revision Date: 09.04.2021		9S Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017			
F	Result		:	negative				
А Е	Species Application Route Exposure time Result		:	Mouse oral (feed) 104 weeks negative				
5	Sodiun	n n-dodecyl sulfate:						
	Species	-		Rat				
		, tion Route	÷	Ingestion				
		re time	÷	2 Years				
	Method		:	OECD Test Guide	line 453			
	Result		:	negative				
F	Remark	S	:	Based on data fro	m similar materials			
	•	l uctive toxicity ssified based on availa	blo	information				
	Compo		DIE	inionnation.				
	Enatim	ha						
	Ezetim				, , , , , , ,			
E	Effects on fertility		:	 Test Type: Fertility/early embryonic development Species: Rat, male and female Fertility: NOAEL: > 1,000 mg/kg body weight Result: No effects on fertility, No fetotoxicity 				
	Effects on foetal develop- ment		:	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: > 1,000 mg/kg body wei Result: No adverse effects Test Type: Development Species: Rabbit Application Route: Oral				
				Developmental To Result: No advers	oxicity: NOAEL: > 1,000 mg/kg body weight e effects			
5	Sodiun	n n-dodecyl sulfate:						
E	Effects	on fertility	:	Species: Rat Application Route Method: OECD To Result: negative				
	Effects ment	on foetal develop-	:	Species: Rat Application Route Result: negative	o-foetal development : Ingestion on data from similar materials			

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021		DS Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017						
	T - single exposure lassified based on avai	ilable	information.							
STO	T - repeated exposure	•								
Not c	Not classified based on available information.									
Repe	Repeated dose toxicity									
<u>Com</u>	ponents:									
Ezeti	mibe:									
		:	Dog 1,000 mg/kg Oral 90 d							
Rema		:	No significant ad	dverse effects were reported						
	EL cation Route sure time	:	Rat 1,500 mg/kg Oral 90 d No significant ad	dverse effects were reported						
	EL cation Route sure time		Mouse 500 mg/kg Oral 90 d No significant ad	dverse effects were reported						
	EL cation Route sure time	:	Dog 300 mg/kg Oral 1 yr No significant ac	dverse effects were reported						
Spec NOA Appli	EL cation Route		Rat 488 mg/kg Ingestion							
Expo	sure time	:	90 Days							

Aspiration toxicity

Not classified based on available information.


Components:

Ezetimibe:

Remarks

Not applicable

: Based on data from similar materials





Version 2.6	Revision Date: 09.04.2021		OS Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017			
Exp	erience with human exp	osi	ire				
Com	ponents:						
Ezet	imibe:						
Inge	Ingestion		Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatu- lence, muscle pain, upper respiratory tract infection, Back pain, joint pain				
SECTIO	N 12: Ecological infor	ma	tion				
12.1 Tox	icity						
<u>Com</u>	nponents:						
Ezet	imibe:						
Toxi	city to fish	:	Exposure time: 96 Method: OECD To				
	city to daphnia and other atic invertebrates	:	Exposure time: 48 Method: OECD Te				
Toxi plan	city to algae/aquatic ts	:	0.317 mg/l Exposure time: 96 Method: OECD To				
			mg/I Exposure time: 96 Method: OECD Te				
Toxi	city to microorganisms	:	EC50 : > 4.4 mg/l Exposure time: 3 Test Type: Respir Method: OECD To Remarks: No toxic	h ration inhibition			
			NOEC : 4.4 mg/l Exposure time: 3 Test Type: Respir Method: OECD To Remarks: No toxi	ation inhibition			
Toxi icity)	city to fish (Chronic tox-	:	NOEC: 0.051 mg/ Exposure time: 33 Species: Pimepha Method: OECD Te	3 d ales promelas (fathead minnow)			

according to Regulation (EC) No. 1907/2006



			d don variegatus (sheepshead minnow) icity at the limit of solubility	
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)		NOEC: 0.282 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Remarks: No toxicity at the limit of solubility		
or (Chronic aquatic	:	1		
n n-dodecyl sulfate: to fish	:		es promelas (fathead minnow)): 29 mg/l 6 b	
	:	•	nnia dubia (water flea)): 5.55 mg/l	
Toxicity to algae/aquatic plants		•	esmus subspicatus (green algae)): > 120 mg	
		NOEC (Desmode Exposure time: 7	esmus subspicatus (green algae)): 30 mg/l 2 h	
Toxicity to microorganisms		EC50 : 135 mg/l Exposure time: 3	h	
Toxicity to fish (Chronic tox- icity)		NOEC: >= 1.357 mg/l Exposure time: 42 d Species: Pimephales promelas (fathead minnow)		
ty to daphnia and other c invertebrates (Chron- city)		NOEC: 0.88 mg/l Exposure time: 7 d Species: Ceriodaphnia dubia (water flea)		
ence and degradabili	ity			
onents:				
i be: adability	:	Result: Not readi Biodegradation: Exposure time: 2	6.8 %	
in water	:	: Hydrolysis: 50 %(4.5 d) Method: OECD Test Guideline 111		
n n-dodecyl sulfate: adability	:	Result: Readily b		
	ay) or (Chronic aquatic n-dodecyl sulfate: to fish to daphnia and other invertebrates to algae/aquatic to microorganisms to fish (Chronic tox- to daphnia and other invertebrates (Chron- y) ence and degradability nents: be: adability in water	ay) or (Chronic aquatic : n-dodecyl sulfate: to fish : to daphnia and other : invertebrates to algae/aquatic : to microorganisms : to fish (Chronic tox- : to daphnia and other : invertebrates (Chron- ty) ence and degradability nents: be: adability : in water : n-dodecyl sulfate:	ty)Species: Daphnia Remarks: No toxor (Chronic aquatic1 n-dodecyl sulfate: to fish1to fish:LC50 (Pimephale Exposure time: 9to daphnia and other invertebrates:EC50 (Ceriodaph Exposure time: 4to algae/aquatic:ErC50 (Desmode Exposure time: 7NOEC (Desmode Exposure time: 7to microorganisms:EC50 : 135 mg/l Exposure time: 3to fish (Chronic tox-:NOEC: >= 1.357 Exposure time: 4 Species: Pimephto daphnia and other invertebrates (Chron- ty):NOEC: 0.88 mg/l Exposure time: 7 Species: Ceriodaence and degradability ments: be: adability:nents: bi: adability:nents: in water:he: an-dodecyl sulfate::	

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021		DS Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017	
			Exposure time: 2 Method: OECD 1	28 d Fest Guideline 301B	
12.3 Bioa	ccumulative potential				
<u>Com</u>	ponents:				
Ezeti	mibe:				
Bioad	ccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Exposure time: 97 d Bioconcentration factor (BCF): 173 Method: OECD Test Guideline 305		
	ion coefficient: n- ol/water	:	log Pow: 4.36		
Sodium n-dodecyl sulfate: Partition coefficient: n- octanol/water		:	log Pow: 0.83		
12.4 Mob	ility in soil				
<u>Com</u>	ponents:				
Ezeti	mibe:				
	Distribution among environ- mental compartments		log Koc: 4.35 Method: OECD 1	Test Guideline 106	
12.5 Resu	ilts of PBT and vPvB a	sse	ssment		
Prod	uct:				
Assessment		:	to be either persi	nixture contains no components considered istent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of	
12.6 Othe	r adverse effects				
Prod	<u>uct:</u>				
Endo tial	crine disrupting poten-	:	ered to have end REACH Article 5	nixture does not contain components consid- locrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.	
SECTIO	N 13: Disposal consi	der	ations		
13.1 Was	te treatment methods				
Product		:	According to the are not product s	cordance with local regulations. European Waste Catalogue, Waste Codes specific, but application specific. buld be assigned by the user, preferably in	

Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

according to Regulation (EC) No. 1907/2006



Version 2.6	Revision Date: 09.04.2021		0S Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017				
Contaminated packaging			 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. 					
SECTION	14: Transport infor	mat	ion					
14.1 UN n	umber							
ADN		:	UN 3077					
ADR		:	UN 3077					
RID		:	UN 3077					
IMDG	i	:	UN 3077					
ΙΑΤΑ		:	UN 3077					
14.2 UN p	roper shipping name							
ADN		:	ENVIRONMENTA N.O.S. (Ezetimibe)	ALLY HAZARDOUS SUBSTANCE, SOLID,				
ADR		:	ENVIRONMENTA N.O.S. (Ezetimibe)	LLY HAZARDOUS SUBSTANCE, SOLID,				
RID		:	ENVIRONMENTA N.O.S. (Ezetimibe)	LLY HAZARDOUS SUBSTANCE, SOLID,				
IMDG	i	:	ENVIRONMENTA N.O.S. (Ezetimibe)	LLY HAZARDOUS SUBSTANCE, SOLID,				
ΙΑΤΑ		:	Environmentally h (Ezetimibe)	azardous substance, solid, n.o.s.				
14.3 Trans	sport hazard class(es)							
ADN		:	9					
ADR		:	9					
RID		:	9					
IMDG	i	:	9					
ΙΑΤΑ		:	9					
14.4 Pack	ing group							
Class	ng group ification Code rd Identification Number s	::	III M7 90 9					
Packi	ng group ification Code	:	III M7					

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version 2.6	Revision Date: 09.04.2021		0S Number: 67794-00009	Date of last issue: 10.10.2020 Date of first issue: 18.04.2017
Lab	zard Identification Number pels nnel restriction code	:	90 9 (-)	
Cla Ha:) cking group ssification Code zard Identification Number pels	:	III M7 90 9	
Lat	DG cking group bels S Code	:	III 9 F-A, S-F	
Pao airc Pao Pao	A (Cargo) cking instruction (cargo craft) cking instruction (LQ) cking group pels	:	956 Y956 III Miscellaneous	
Pao ger Pao Pao	TA (Passenger) cking instruction (passen- aircraft) cking instruction (LQ) cking group pels	: : : : :	956 Y956 III Miscellaneous	
14.5 En	vironmental hazards			
AD Env	N vironmentally hazardous	:	yes	
AD Env	R <i>v</i> ironmentally hazardous	:	yes	
RIE Env) vironmentally hazardous	:	yes	
I MI Ma	DG rine pollutant	:	yes	
	A (Passenger) vironmentally hazardous	:	yes	
Env	A (Cargo) vironmentally hazardous	:	yes	

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.



according to Regulation (EC) No. 1907/2006

Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1567794-00009	Date of first issue: 18.04.2017

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL	200 t	500 t
	HAZARDS		

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	•	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.			
Full text of H-Statements					
H302	:	Harmful if swallowed.			
H315	:	Causes skin irritation.			
H318	:	Causes serious eye damage.			
H410	:	Very toxic to aquatic life with long lasting effects.			
H412	:	Harmful to aquatic life with long lasting effects.			
Full text of other abbreviations					
Acute Tox.	:	Acute toxicity			
Aquatic Chronic	:	Long-term (chronic) aquatic hazard			
Eye Dam.	:	Serious eye damage			
Skin Irrit.	:	Skin irritation			



Ezetimibe Granules Formulation

Version	Revision Date:	 DS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	67794-00009	Date of first issue: 18.04.2017
	140 140 / TWA 140 / STEL	Long-term expo	- Workplace Exposure Limits sure limit (8-hour TWA reference period) osure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Aquatic Chronic 2	H411	Calculation method
Aquatic Chronic 2	H411	Calculation metho

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

according to Regulation (EC) No. 1907/2006



Ezetimibe Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.6	09.04.2021	1567794-00009	Date of first issue: 18.04.2017

GB / EN